id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
USDA_FRDOC_0001-3267,USDA,USDA_FRDOC_0001,"Agency Information Collection Activities; Proposals, Submissions, and Approvals",Notice,,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T18:14:56Z,2026-03979,0,0,09000064b91e323f
FWS-R5-MB-2025-1497-0001,FWS,FWS-R5-MB-2025-1497,Agency Information Collection Activities; Northeast Region Hunter Participation Surveys,Notice,,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T17:57:25Z,2026-03946,1,0,09000064b91df85a
FWS-R5-MB-2025-1497-0002,FWS,FWS-R5-MB-2025-1497,3-2558 Spring Turkey Hunter Participation Survey Rev 12-2025 w-changes highlighted 12192025,Supporting & Related Material,,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T18:14:43Z,,0,0,09000064b91df736
FWS-R5-MB-2025-1497-0003,FWS,FWS-R5-MB-2025-1497,3-2557 Hunter Participation Survey Rev 12-2025 w-changes highlighted 12192025,Supporting & Related Material,,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T18:14:43Z,,0,0,09000064b91df737
FDA-2026-H-1967-0001,FDA,FDA-2026-H-1967,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T00:52:27Z,,0,0,09000064b91e2c80
FDA-2026-P-2144-0004,FDA,FDA-2026-P-2144,Attachment 2,Supporting & Related Material,Background Material,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T22:06:16Z,,0,0,09000064b91e2fcb
FDA-2026-H-1966-0001,FDA,FDA-2026-H-1966,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T00:42:04Z,,0,0,09000064b91e3d80
FDA-2026-H-1789-0001,FDA,FDA-2026-H-1789,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T23:48:46Z,,0,0,09000064b91e3834
FDA-2026-N-1628-0001,FDA,FDA-2026-N-1628,International Drug Scheduling; Convention on Psychotropic Substances; Single Convention on Narcotic Drugs; Scheduling Recommendations; N-Pyrrolidino Isotonitazene; N-Desethyl Etonitazene; Coca Leaf; MDMB-FUBINACA; Request for Comments,Notice,Request for Comments,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-03-06T04:59:59Z,2026-02-27T20:18:13Z,2026-03914,1,0,09000064b91e31af
FDA-2007-D-0369-2525,FDA,FDA-2007-D-0369,PSG_219104 - Draft Guidance on Letermovir,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:52:13Z,,1,0,09000064b91e01dd
FDA-2007-D-0369-2524,FDA,FDA-2007-D-0369,PSG_219097 - Draft Guidance on Imatinib Mesylate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:51:42Z,,1,0,09000064b91e01db
FDA-2007-D-0369-2521,FDA,FDA-2007-D-0369,PSG_218550 - Draft Guidance on Entrectinib,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:50:35Z,,1,0,09000064b91e01d5
FDA-2007-D-0369-2519,FDA,FDA-2007-D-0369,PSG_218316 - Draft Guidance on Semaglutide,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:49:49Z,,1,0,09000064b91e01d1
FDA-2007-D-0369-2526,FDA,FDA-2007-D-0369,PSG_220073 - Draft Guidance on Apixaban,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:52:29Z,,1,0,09000064b91e01f3
FDA-2007-D-0369-2437,FDA,FDA-2007-D-0369,PSG_019758 - Draft Guidance on Clozapine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:20:28Z,,1,0,09000064b91df4ce
FDA-2007-D-0369-2433,FDA,FDA-2007-D-0369,PSG_018731 - Draft Guidance on Buspirone Hydrochloride,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:19:11Z,,1,0,09000064b91df467
FDA-2007-D-0369-2445,FDA,FDA-2007-D-0369,PSG_020310 - Draft Guidance on Ketoconazole,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:22:59Z,,1,0,09000064b91df4ee
FDA-2007-D-0369-2452,FDA,FDA-2007-D-0369,PSG_020870 - Draft Guidance on Estradiol; Norethindrone Acetate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:25:03Z,,1,0,09000064b91e0106
FDA-2007-D-0369-2463,FDA,FDA-2007-D-0369,PSG_021590 - Draft Guidance on Clozapine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:30:34Z,,1,0,09000064b91e0127
FDA-2007-D-0369-2471,FDA,FDA-2007-D-0369,PSG_022549 - Draft Guidance on Loxapine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:33:45Z,,1,0,09000064b91e0138
FDA-2007-D-0369-2499,FDA,FDA-2007-D-0369,PSG_214187 - Draft Guidance on Sofosbuvir; Velpatasvir,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:43:04Z,,1,0,09000064b91e018e
FDA-2007-D-0369-2474,FDA,FDA-2007-D-0369,PSG_202155 - Draft Guidance on Apixaban,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:34:51Z,,1,0,09000064b91e013e
FDA-2007-D-0369-2504,FDA,FDA-2007-D-0369,PSG_215110 - Draft Guidance on Glecaprevir; Pibrentasvir,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:44:51Z,,1,0,09000064b91e0198
FDA-2007-D-0369-2502,FDA,FDA-2007-D-0369,PSG_214826 - Draft Guidance on Lorazepam,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:44:20Z,,1,0,09000064b91e0194
FDA-2007-D-0369-2487,FDA,FDA-2007-D-0369,PSG_210136 - Draft Guidance on Buprenorphine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:39:03Z,,1,0,09000064b91e016c
FDA-2026-H-1924-0001,FDA,FDA-2026-H-1924,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T17:54:21Z,,0,0,09000064b91e2df0
FDA-2026-H-1422-0001,FDA,FDA-2026-H-1422,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T18:07:36Z,,0,0,09000064b91df74e
FDA-2025-P-4612-0004,FDA,FDA-2025-P-4612,"Final Response Letter from FDA CDER to Arnall Golden Gregory, LLP",Other,Denial of Petition,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T20:03:31Z,,0,0,09000064b91e0bd2
FDA-2007-D-0369-2518,FDA,FDA-2007-D-0369,PSG_217514 - Draft Guidance on Dabrafenib Mesylate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:49:32Z,,1,0,09000064b91e01cf
FDA-2007-D-0369-2505,FDA,FDA-2007-D-0369,PSG_215352 - Draft Guidance on Phenylephrine Hydrochloride; Tropicamide,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:45:07Z,,1,0,09000064b91e019a
FDA-2007-D-0369-2470,FDA,FDA-2007-D-0369,PSG_022395 - Draft Guidance on Capsaicin,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:33:25Z,,1,0,09000064b91e0135
FDA-2007-D-0369-2468,FDA,FDA-2007-D-0369,PSG_022198 - Draft Guidance on Granisetron,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:32:47Z,,1,0,09000064b91e0131
FDA-2007-D-0369-2483,FDA,FDA-2007-D-0369,PSG_208036 - Draft Guidance on Barium Sulfate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:37:51Z,,1,0,09000064b91e015a
FDA-2007-D-0369-2465,FDA,FDA-2007-D-0369,PSG_021986 - Draft Guidance on Dasatinib,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:31:13Z,,1,0,09000064b91e012b
FDA-2007-D-0369-2478,FDA,FDA-2007-D-0369,PSG_205395 - Draft Guidance on Cobicistat; Darunavir Ethanolate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:36:14Z,,1,0,09000064b91e0150
FDA-2007-D-0369-2430,FDA,FDA-2007-D-0369,PSG_017628 - Draft Guidance on Tolmetin Sodium,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:18:11Z,,1,0,09000064b91df461
FDA-2007-D-0369-2450,FDA,FDA-2007-D-0369,PSG_020612 - Draft Guidance on Lidocaine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:24:27Z,,1,0,09000064b91df4f8
FDA-2007-D-0369-2451,FDA,FDA-2007-D-0369,PSG_020831 - Draft Guidance on Formoterol Fumarate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:24:44Z,,1,0,09000064b91e0104
FDA-2007-D-0369-2455,FDA,FDA-2007-D-0369,PSG_021258 - Draft Guidance on Estradiol; Levonorgestrel,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:25:50Z,,1,0,09000064b91e010c
FDA-2007-D-0369-2436,FDA,FDA-2007-D-0369,PSG_019081 - Draft Guidance on Estradiol,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:20:10Z,,1,0,09000064b91df4cc
FDA-2026-H-1972-0001,FDA,FDA-2026-H-1972,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T01:27:00Z,,0,0,09000064b91e451b
FDA-2026-H-1968-0001,FDA,FDA-2026-H-1968,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T01:29:56Z,,0,0,09000064b91e451e
FDA-1991-N-0191-0001,FDA,FDA-1991-N-0191,"CIVIL MONEY PENALTIES: BIOLOGICS, DRUGS, AND MEDICAL DEVICES",Proposed Rule,Notice of Proposed Rulemaking (NPRM),2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,1993-07-27T03:59:59Z,2026-02-28T01:41:45Z,93-12314,0,0,090000648052de75
FDA-2026-H-1958-0001,FDA,FDA-2026-H-1958,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T23:55:07Z,,0,0,09000064b91e3874
FDA-2026-H-1786-0001,FDA,FDA-2026-H-1786,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T22:57:13Z,,0,0,09000064b91e30c0
FDA-2026-P-2144-0001,FDA,FDA-2026-P-2144,"Suitability Petition from Hyman, Phelps & McNamara, P.C.",Other,Petition(s),2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T22:05:51Z,,1,0,09000064b91e3853
FDA-2026-P-1300-0005,FDA,FDA-2026-P-1300,Suitability Petition Amendment from APDM Pharmaceuticals Private Limited,Other,Amendment,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T23:32:34Z,,1,0,09000064b91e3c62
FDA-2026-N-1486-0001,FDA,FDA-2026-N-1486,Issuance of Priority Review Voucher; Rare Pediatric Disease Product; ZYCUBO (Copper Histidinate),Notice,Announcement,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T20:11:11Z,2026-03925,0,0,09000064b91e323b
FDA-2007-D-0369-2458,FDA,FDA-2007-D-0369,PSG_021351 - Draft Guidance on Oxybutynin,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:27:00Z,,1,0,09000064b91e011d
FDA-2007-D-0369-2510,FDA,FDA-2007-D-0369,PSG_216318 - Draft Guidance on Testosterone Cypionate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:46:43Z,,1,0,09000064b91e01b1
FDA-2007-D-0369-2513,FDA,FDA-2007-D-0369,PSG_216675 - Draft Guidance on Perfluorohexyloctane,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:47:39Z,,1,0,09000064b91e01b8
FDA-2007-D-0369-2462,FDA,FDA-2007-D-0369,PSG_021588 - Draft Guidance on Imatinib Mesylate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:29:47Z,,1,0,09000064b91e0125
FDA-2007-D-0369-2449,FDA,FDA-2007-D-0369,PSG_020538 - Draft Guidance on Estradiol,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:24:10Z,,1,0,09000064b91df4f6
FDA-2007-D-0369-2431,FDA,FDA-2007-D-0369,PSG_017874 - Draft Guidance on Scopolamine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:18:30Z,,1,0,09000064b91df463
FDA-2007-D-0369-2434,FDA,FDA-2007-D-0369,PSG_018859 - Draft Guidance on Ribavirin,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:19:33Z,,1,0,09000064b91df4c8
FDA-2007-D-0369-2496,FDA,FDA-2007-D-0369,PSG_213004 - Draft Guidance on Amoxicillin; Omeprazole Magnesium; Rifabutin,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:41:55Z,,1,0,09000064b91e0188
FDA-2007-D-0369-2477,FDA,FDA-2007-D-0369,PSG_204017 - Draft Guidance on Ethinyl Estradiol; Levonorgestrel,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:35:51Z,,1,0,09000064b91e014e
FDA-2007-D-0369-2491,FDA,FDA-2007-D-0369,PSG_212268 - Draft Guidance on Asenapine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:40:16Z,,1,0,09000064b91e017e
FDA-2007-D-0369-2501,FDA,FDA-2007-D-0369,PSG_214522 - Draft Guidance on Tadalafil,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:44:01Z,,1,0,09000064b91e0192
FDA-2007-D-0369-2485,FDA,FDA-2007-D-0369,PSG_208171 - Draft Guidance on Ferric Derisomaltose,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:38:28Z,,1,0,09000064b91e015e
FDA-2007-D-0369-2472,FDA,FDA-2007-D-0369,PSG_050440 - Draft Guidance on Cephalexin,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:34:04Z,,1,0,09000064b91e013a
FDA-2007-D-0369-2498,FDA,FDA-2007-D-0369,PSG_213953 - Draft Guidance on Testosterone Undecanoate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:42:31Z,,1,0,09000064b91e018c
FDA-2007-D-0369-2493,FDA,FDA-2007-D-0369,PSG_212306 - Draft Guidance on Selinexor,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:40:55Z,,1,0,09000064b91e0182
FDA-2007-D-0369-2503,FDA,FDA-2007-D-0369,PSG_215039 - Draft Guidance on Alpelisib,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:44:36Z,,1,0,09000064b91e0196
FDA-2007-D-0369-2492,FDA,FDA-2007-D-0369,PSG_212304 - Draft Guidance on Donepezil Hydrochloride,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:40:33Z,,1,0,09000064b91e0180
FDA-2026-H-1964-0001,FDA,FDA-2026-H-1964,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T01:59:24Z,,0,0,09000064b91e4522
FDA-1991-N-0191-0002,FDA,FDA-1991-N-0191,Request for Extension from Health Industry Manufacturers Association,Other,Request for Extension,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T01:44:11Z,,0,0,090000648052de80
FDA-1991-N-0191-0010,FDA,FDA-1991-N-0191,"Civil Money Penalties; Biologics, Drugs, and Medical Devices; Extension of Comment Period; Correction and Addition
Period; Correction and Addition",Notice,Notice of Extension,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,1993-08-26T03:59:59Z,2026-02-28T02:00:09Z,93-17833,0,0,090000648052deaf
FDA-2026-P-2144-0002,FDA,FDA-2026-P-2144,"Acknowledgement Letter from FDA DMB to Hyman, Phelps & McNamara, P.C.",Other,Acknowledgement Letter/Receipt,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T22:06:07Z,,0,0,09000064b91e3859
FDA-2026-P-1300-0007,FDA,FDA-2026-P-1300,"Attachment 2 - RLD BELSOMRA® (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Approval Letter",Supporting & Related Material,Background Material,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T23:33:00Z,,0,0,09000064b91e3e1a
FDA-2007-D-0369-2456,FDA,FDA-2007-D-0369,PSG_021306 - Draft Guidance on Buprenorphine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:26:18Z,,1,0,09000064b91e0119
FDA-2007-D-0369-2428,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T19:14:17Z,2026-03963,0,0,09000064b91e3271
FDA-2026-H-1971-0001,FDA,FDA-2026-H-1971,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T01:24:53Z,,0,0,09000064b91e30c9
FDA-2026-H-1965-0001,FDA,FDA-2026-H-1965,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-28T00:10:55Z,,0,0,09000064b91e3d4b
FDA-2026-P-1300-0006,FDA,FDA-2026-P-1300,"Attachment 1 - RLD BELSOMRA® (Suvorexant) Tablets 5 mg, 10 mg, 15 mg and 20 mg Package Insert",Supporting & Related Material,Background Material,2026-02-27T05:00:00Z,2026,2,,,2026-02-27T23:32:57Z,,0,0,09000064b91e3e19
FDA-2026-H-1785-0001,FDA,FDA-2026-H-1785,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T22:16:22Z,,0,0,09000064b91e37f3
FDA-2026-H-1782-0001,FDA,FDA-2026-H-1782,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T23:01:08Z,,0,0,09000064b91e3e15
FDA-2026-H-1961-0001,FDA,FDA-2026-H-1961,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T22:13:46Z,,0,0,09000064b91e2bfe
FDA-2026-H-1960-0001,FDA,FDA-2026-H-1960,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T21:40:48Z,,0,0,09000064b91e2fce
FDA-2023-N-0119-0020,FDA,FDA-2023-N-0119,"Fiscal Year 2026 Generic Drug Science and Research Initiatives Workshop; Public Workshop; Request for
Comments",Notice,Request for Comments,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-07-11T03:59:59Z,2026-02-27T19:57:39Z,2026-03961,1,0,09000064b91e326c
FDA-2007-D-0369-2480,FDA,FDA-2007-D-0369,PSG_206968 - Draft Guidance on Acetaminophen,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:36:59Z,,1,0,09000064b91e0154
FDA-2007-D-0369-2515,FDA,FDA-2007-D-0369,PSG_217202 - Draft Guidance on Landiolol Hydrochloride,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:48:39Z,,1,0,09000064b91e01bc
FDA-2007-D-0369-2517,FDA,FDA-2007-D-0369,PSG_217370 - Draft Guidance on Acoltremon,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:49:14Z,,1,0,09000064b91e01cd
FDA-2007-D-0369-2514,FDA,FDA-2007-D-0369,PSG_216962 - Draft Guidance on Foscarbidopa; Foslevodopa,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:48:20Z,,1,0,09000064b91e01ba
FDA-2007-D-0369-2523,FDA,FDA-2007-D-0369,PSG_219016 - Draft Guidance on Rilpivirine Hydrochloride,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:51:25Z,,1,0,09000064b91e01d9
FDA-2007-D-0369-2482,FDA,FDA-2007-D-0369,PSG_207962 - Draft Guidance on Lidocaine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:37:34Z,,1,0,09000064b91e0158
FDA-2007-D-0369-2476,FDA,FDA-2007-D-0369,PSG_203479 - Draft Guidance on Clozapine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:35:30Z,,1,0,09000064b91e014c
FDA-2007-D-0369-2495,FDA,FDA-2007-D-0369,PSG_212526 - Draft Guidance on Alpelisib,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:41:39Z,,1,0,09000064b91e0186
FDA-2007-D-0369-2484,FDA,FDA-2007-D-0369,PSG_208143 - Draft Guidance on Barium Sulfate,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:38:13Z,,1,0,09000064b91e015c
FDA-2007-D-0369-2494,FDA,FDA-2007-D-0369,PSG_212516 - Draft Guidance on Duloxetine Hydrochloride,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:41:20Z,,1,0,09000064b91e0184
FDA-2007-D-0369-2500,FDA,FDA-2007-D-0369,PSG_214410 - Draft Guidance on Baloxavir Marboxil,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:43:31Z,,1,0,09000064b91e0190
FDA-2026-H-1922-0001,FDA,FDA-2026-H-1922,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T18:45:55Z,,0,0,09000064b91dfe38
FDA-2007-D-0369-2454,FDA,FDA-2007-D-0369,PSG_021234 - Draft Guidance on Diclofenac Epolamine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:25:35Z,,1,0,09000064b91e010a
FDA-2007-D-0369-2448,FDA,FDA-2007-D-0369,PSG_020489 - Draft Guidance on Testosterone,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:23:57Z,,1,0,09000064b91df4f4
FDA-2007-D-0369-2439,FDA,FDA-2007-D-0369,PSG_019927 - Draft Guidance on Ketoconazole,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:21:03Z,,1,0,09000064b91df4d2
FDA-2007-D-0369-2453,FDA,FDA-2007-D-0369,PSG_021180 - Draft Guidance on Ethinyl Estradiol; Norelgestromin,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:25:18Z,,1,0,09000064b91e0108
FDA-2007-D-0369-2435,FDA,FDA-2007-D-0369,PSG_018891 - Draft Guidance on Clonidine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:19:51Z,,1,0,09000064b91df4ca
FDA-2007-D-0369-2441,FDA,FDA-2007-D-0369,PSG_020076 - Draft Guidance on Nicotine,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:21:38Z,,1,0,09000064b91df4d6
FDA-2007-D-0369-2429,FDA,FDA-2007-D-0369,PSG_012283 - Draft Guidance on Chlorthalidone,Other,Guidance,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,2026-04-29T03:59:59Z,2026-02-27T19:17:46Z,,1,0,09000064b91df45f
FDA-2026-H-1420-0001,FDA,FDA-2026-H-1420,Complaint,Other,Complaint,2026-02-27T05:00:00Z,2026,2,2026-02-27T05:00:00Z,,2026-02-27T23:42:51Z,,0,0,09000064b91e3818